Sarcoma 
Welcome,         Profile    Billing    Logout  

521 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Sarcoma
2022-002311-39: Use of Ketotifen to enhance treatment efficacy in patients with sarcoma

Ongoing
2
10
RoW
Tablet, Zaditen
University Of Cyprus, European Research Council Executive Agency (ERCEA)
Patients with sarcoma, Patients that suffer from a type of cancer, known as sarcoma, Diseases [C] - Cancer [C04]
 
 
E7080-G000-231, NCT04447755 / 2019-004441-33: A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080)

Active, not recruiting
2
127
Europe, US, RoW
Lenvatinib, MK-7902, E7080, LENVIMA
Merck Sharp & Dohme LLC, Eisai Inc.
Relapsed or Refractory Solid Tumors
09/22
02/25
NCT05993299: Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma

Active, not recruiting
2
7
Europe, Canada, US
Letetresgene autoleucel, Cyclophosphamide, Fludarabine
GlaxoSmithKline
Neoplasms
10/22
07/24
DICE, NCT03648489: Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma)

Active, not recruiting
2
134
Europe
Paclitaxel, TAK228
Imperial College London, Takeda Pharmaceuticals International, Inc., North Eastern German Society of Gynaecological Oncology
Ovarian Cancer, Ovarian Neoplasms, Ovarian Carcinosarcoma, Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Fallopian Tube Cancer, Fallopian Tube Neoplasms, Primary Peritoneal Carcinoma, Primary Peritoneal Serous Adenocarcinoma
12/22
12/22
NCT03719430: APX005M and Doxorubicin in Advanced Sarcoma

Active, not recruiting
2
27
US
Doxorubicin, ADRIAMYCIN, APX005M, APX-005M
Alexander Z. Wei, MD, Apexigen America, Inc.
Soft Tissue Sarcoma
12/24
12/25
NCT02203760 / 2012-003810-15: Pazopanib vs. Pazopanib Plus Gemcitabine

Active, not recruiting
2
58
Europe
Pazopanib plus Gemcitabine, Votrient and Gemzar, Pazopanib, Votrient
North Eastern German Society of Gynaecological Oncology, Novartis Pharmaceuticals, medac GmbH
Leiomyosarcoma or Carcinosarcoma
12/24
12/24
AcSé Pembrolizumab study, NCT03012620 / 2016-002260-14: Secured Access to Pembrolizumab for Patients With Selected Rare Cancer Types

Completed
2
334
Europe
Pembrolizumab, MK-3475, KEYTRUDA
UNICANCER, National Cancer Institute, France, Ligue contre le cancer, France, Merck Sharp & Dohme LLC
Sarcoma, Ovarian Neoplasm, Central Nervous System Neoplasm, Thyroid Neoplasm, Carcinoma, Neuroendocrine, Neoplasms, Germ Cell and Embryonal, NK/T-cell Lymphoma
12/22
12/23
AAAQ8661, NCT02978859: Sitravatinib in Advanced Liposarcoma and Other Soft Tissue Sarcomas

Active, not recruiting
2
29
US
MGCD516, Sitravatinib
Matthew Ingham, Mirati Therapeutics Inc.
Liposarcoma, Metastatic Liposarcoma
01/23
01/23
HopES, NCT03778996: SM-88 Maintenance Therapy for Advanced Ewing's Sarcoma and as Salvage Therapy for Sarcoma

Active, not recruiting
2
31
US
Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), SM-88
Sarcoma Oncology Research Center, LLC, Tyme, Inc
Sarcoma, Ewing, Sarcoma
12/24
03/25
NCT04076579: Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma

Active, not recruiting
2
29
US
Olaparib, Trabectedin
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC, AstraZeneca
Sarcoma, Sarcoma Metastatic
01/23
01/25
COPELIA, NCT03570437: Does Cediranib With Paclitaxel, or Cediranib and Olaparib, Treat Advanced Endometrial Cancer Better Than Paclitaxel?

Active, not recruiting
2
124
Europe
Paclitaxel, L01CD01, Cediranib, AZD2171, 288383-20-0, Olaparib, AZD2281, Lynparza, L01XX46
University of Manchester, AstraZeneca, Cardiff University
Carcinosarcoma, Endometrial Neoplasms
01/23
06/23
NCT01903330: ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Checkmark Interim results in combination with ERC1671/GM CSF/cyclophosphamide for recurrent glioblastoma
Aug 2020 - Aug 2020: Interim results in combination with ERC1671/GM CSF/cyclophosphamide for recurrent glioblastoma
Active, not recruiting
2
84
US
ERC1671, Gliovac, GM-CSF, Leukine®, sargramostim, Cyclophosphamide, 2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate, Oral Control (Sucrose pill), Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%)), Bevacizumab/Bevacizumab Biosimilar, Avastin, MVASI, bevacizumab-awwb, bevacizumab-bvzr, ZIRABEV
Epitopoietic Research Corporation, University of California, Irvine
Glioblastoma, Gliosarcoma
03/23
03/23
PROACT, NCT03862131: PROactive Evaluation of Function to Avoid CardioToxicity

Active, not recruiting
2
49
US
MyoStrain®, Cardiac MRI Imaging Software, Intramyocardial Strain
Washington University School of Medicine, Myocardial Solutions
Cardiotoxicity, Breast Cancer, Lymphoma, Sarcoma, Leukemia, Myeloma, Lung Cancer
07/24
07/24
EndoBARR, NCT03694262: The Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

Completed
2
30
US
Rucaparib, Rubraca, Bevacizumab, Avastin, Atezolizumab, Tecentriq
Medical College of Wisconsin, Genentech, Inc., Clovis Oncology, Inc.
Endometrial Cancer, Uterine Carcinosarcoma
03/23
04/23
2022-003845-36: Phase II study evaluating the efficacy and safety of preoperative immunotherapy (pembrolizumab with eftilagimod alfa) in combination with radiotherapy in patients with operable soft tissue sarcomas.

Ongoing
2
40
Europe
EFTILAGIMOD ALPHA, PEMBROLIZUMAB, IMP321, Solution for injection, , Keytruda
Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy, Medical Research Agency, Immutep
Resectable soft tissue sarcomas, a sarcoma that qualifies for surgical treatment, Diseases [C] - Cancer [C04]
 
 
2023-000169-14: Clinical Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma Studio clinico su Treosulfan/Melfalan ad alte dosi come trattamento di consolidamento nel sarcoma di Ewing ad alto e altissimo rischio di nuova diagnosi

Not yet recruiting
2
60
Europe
Trecondi, Vincristina, Cyclophosphamide, Doxorubicin, Ifosfamide, Etoposide, Melphalan, Powder for solution for infusion, Solution for injection, Powder for injection, Concentrate for solution for infusion, Powder and solvent for solution for injection/infusion, TRECONDI 1 g, TRECONDI 5 g
Fondazione Santobono Pausilipon ONLUS, Medac Gesellschaft für klinische Spezialpräparate m.b.H.,
Ewing Sarcoma Sarcoma di Ewing, Ewing sarcoma, a bone tumor affecting children, adolescents and young adults Sarcoma di Ewing, un tumore osseo che colpisce bambini, adolescenti e giovani adulti, Diseases [C] - Cancer [C04]
 
 
KX-ORAX-010 , NCT03544567: A Study of Oraxol in Subjects With Cutaneous Angiosarcoma

Completed
2
48
Europe, US, RoW
Oraxol, oral HM30181A + oral paclitaxel
Athenex, Inc.
Angiosarcoma of Skin
05/23
05/23
CAPSTONE, NCT04888429: Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma

Hourglass Jan 2022 - Jun 2022 : Interim data from CAPSTONE trial for NSCLC
Recruiting
2
28
RoW
Camrelizumab, SHR-1210, Famitinib, SHR-1020
Qian Chu, Jiangsu HengRui Medicine Co., Ltd.
Sarcomatoid Carcinoma of Lung
12/23
06/24
NCT04012827: Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma

Recruiting
2
108
RoW
Apatinib Mesylate, doxorubicin, ifosfamide, Apatinib
Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd.
Soft Tissue Sarcoma
06/23
12/23
OAIE, NCT05277480: Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma

Completed
2
81
RoW
Apatinib+IE, IE
Peking University People's Hospital, Jiangsu HengRui Medicine Co., Ltd.
Effect of Drug, Drug, Toxicity
06/23
11/23
CAIRE, NCT04705818: Combining Epigenetic And Immune Therapy to Beat Cancer.

Recruiting
2
173
Europe
Durvalumab, Tazemetostat
Institut Bergonié, AstraZeneca, Epizyme, Inc.
Advanced Solid Tumor, Advanced Colorectal Carcinoma, Advanced Soft-tissue Sarcoma, Advanced Pancreatic Adenocarcinoma, Adult Solid Tumor
07/23
01/25
EFTISARC-NEO, NCT06128863: Pembrolizumab in Combination With Eftilagimod Alpha and Radiotherapy in Neoadjuvant Treatment of Patients With Soft Tissue Sarcoma - Trial

Recruiting
2
40
Europe
Pembrolizumab, Eftilagimod alpha, Keytruda
Maria Sklodowska-Curie National Research Institute of Oncology, Immutep S.A.S.
Neoadjuvant, Immunotherapy, Sarcoma,Soft Tissue, Radiation Therapy
04/25
04/27
NCT06126510: Clinical Study of VG161 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

Recruiting
2
40
RoW
Recombinant Human IL12/15-PDL1B Oncolytic HSV-1 Injection (Vero Cell), VG161
CNBG-Virogin Biotech (Shanghai) Ltd.
Sarcoma
07/25
01/26
NCT03899805: A Phase II Study of Eribulin and Pembrolizumab in Soft Tissue Sarcomas

Active, not recruiting
2
57
US
Eribulin, Halaven, Pembrolizumab, Keytruda
Dana-Farber Cancer Institute, Merck Sharp & Dohme LLC
Sarcoma, Liposarcoma, Leiomyosarcoma, Undifferentiated Pleomorphic Sarcoma
08/25
08/25
NCT03474094: Clinical and Biological Activity of an Anti-PD-L1 (Atezolizumab) in Operable Localised Soft Tissue Sarcomas Patients to be Treated With Radiotherapy

Recruiting
2
69
Europe
Pre-operative radiotherapy followed by 2 cycles of atezolizumab then surgery, 2 cycles of atezolizumab followed by surgery then post-operative radiotherapy, Pre-operative radiotherapy followed by surgery then 2 cycles of atezolizumab.
Centre Leon Berard, Roche Pharma AG
Sarcoma,Soft Tissue
08/23
08/24
TQB2858-Ib-02, NCT05262101: Clinical Trial of TQB2858 Injection in the Treatment of Advanced High-grade Sarcoma

Terminated
2
7
RoW
TQB2858 injection
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Advanced High-grade Sarcoma
06/23
11/23
2019-002947-41: Propranolol as treatment of patients with angiosarcoma before their standard therapy. Propranolol als behandeling van patiënten met angiosarcoom voorafgaand aan hun standaard behandeling.

Not yet recruiting
2
14
Europe
propranolol, Tablet, propranolol
Netherlands Cancer Institute- Antoni van Leeuwenhoek, Netherlands Cancer Institute
Angiosarcoma angiosarcoom, cancer arising from the inner layer of the blood or lymphatic vessels kanker dat uit de binnenste laag van de bloed- of lymfevaten ontstaat, Diseases [C] - Cancer [C04]
 
 
AOST-2121, NCT04974008: Osteosarcoma Maintenance Therapy With OST31-164

Completed
2
39
US
OST31-164
George Clinical Pty Ltd
Bone Cancer
09/23
09/23
NCT01863745: Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment

Completed
2
15
Japan
nilotinib
Novartis Pharmaceuticals
Gastrointestinal Stromal Tumors
10/23
10/23
NCT05864534: Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma

Recruiting
2
25
US
Balstilimab, BAL, Botensilimab, BOT, Liposomal Doxorubicin, DOX, Sonocloud-9 (SC-9), SC-9
Northwestern University, Agenus Inc., CarThera
Newly Diagnosed Glioblastoma, Glioblastoma, Isocitric Dehydrogenase (IDH)-Wildtype, Gliosarcoma, Glioblastoma Multiforme
05/26
08/26
MANTRA-2, NCT05012397: Milademetan in Advanced/Metastatic Solid Tumors

Terminated
2
40
US
RAIN-32, Milademetan
Rain Oncology Inc
Solid Tumors, Head and Neck Carcinoma, Cholangiocarcinoma, Sarcoma, Lung Adenocarcinoma, Bladder Urothelial Carcinoma, Stomach Adenocarcinoma, Breast Cancer Invasive, Ovarian Carcinoma, Cervical Cancer, Non Small Cell Lung Cancer, Gastric Cancer, Biliary Tract Cancer, Melanoma, Pancreas Cancer, MDM2 Gene Amplification, Testicular Germ Cell Tumor, Adrenocortical Carcinoma
10/23
10/23
NCT04028063: Doxorubicin Plus Dual Checkpoint Blockade for Soft Tissue Sarcomas

Recruiting
2
28
US
doxorubicin with AGEN1884 and AGEN2034
University of Colorado, Denver, Agenus Inc.
Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma
11/24
11/25
NCT05138146: A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma

Not yet recruiting
2
70
RoW
609A, doxorubicin hydrochloride
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Sarcoma, Soft Tissue
11/23
12/24
DAPPER, NCT03851614: Basket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors

Active, not recruiting
2
90
Canada
Durvalumab, Imfinzi, Olaparib, Lynparza, AZD2281, Cediranib, AZD2171
University Health Network, Toronto, AstraZeneca
Mismatch Repair Proficient Colorectal Cancer, Pancreatic Adenocarcinoma, Leiomyosarcoma
01/25
01/25
FLASH, NCT04733183: Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma

Recruiting
2
98
Europe
Dacarbazine, DTIC, onfekafusp alfa, L19TNF
Philogen S.p.A.
Soft Tissue Sarcoma
12/24
12/24
TTI-621-03, NCT04996004: A Study to Learn About the Study Medicine (Called Ontorpacept or TTI-621) Given Alone and in Combination With Doxorubicin in People With Leiomyosarcoma

Terminated
2
75
US
Ontorpacept (TTI-621), Ontorpacept / SIRPα-IgG1 Fc, Doxorubicin, Adriamycin
Pfizer
Leiomyosarcoma
12/23
12/23
NCT03890068: Anlotinib Maintenance Treatment for Advanced Soft Tissue Sarcoma

Recruiting
2
48
RoW
Anlotinib Hydrochloride, Anlotinib
Sun Yat-sen University, Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Soft Tissue Sarcoma
12/23
05/24
NCT03668340: AZD1775 in Women With Recurrent or Persistent Uterine Serous Carcinoma or Uterine Carcinosarcoma

Active, not recruiting
2
49
US
AZD1775
Dana-Farber Cancer Institute, AstraZeneca
Uterine Cancer
12/24
12/25
NCT05193214: A Phase II Study for 609A in the Treatment of Advanced Undifferentiated Pleomorphic Sarcoma

Not yet recruiting
2
30
RoW
Recombinant anti-PD-1 humanized monoclonal antibody injection, 609A
Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Sarcoma, Soft Tissue
12/23
12/24
NCT03414229: A Study of Epacadostat, an IDO1 Inhibitor, in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active, not recruiting
2
30
US
Epacadostat, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Incyte Corporation, Merck Sharp & Dohme LLC, M.D. Anderson Cancer Center
Sarcoma
01/25
01/25
NCI-2018-01509, NCT03610490: Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma

Active, not recruiting
2
60
US
Autologous Tumor Infiltrating Lymphocytes MDA-TIL, MDA Autologous TILs, MDA Autologous Tumor Infiltrating Lymphocytes, MDA-TILs, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Interleukin-2, Epidermal Thymocyte Activating Factor, ETAF, IL-2, IL2, IL2 Protein, Interleukin 2, Interleukin 2 Precursor, Interleukin II, Lymphocyte Mitogenic Factor, Mitogenic Factor, Ro-236019, T Cell Growth Factor, T-Cell Growth Factor, TCGF, Thymocyte Stimulating Factor, TSF, Quality-of-Life Assessment, Quality of Life Assessment
M.D. Anderson Cancer Center, Bristol-Myers Squibb, Iovance Biotherapeutics, National Cancer Institute (NCI)
Malignant Solid Neoplasm, Metastatic Colorectal Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Platinum-Resistant Ovarian Carcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Ovarian Carcinosarcoma, Refractory Colorectal Carcinoma, Stage IV Colorectal Cancer AJCC v8, Stage IVA Colorectal Cancer AJCC v8, Stage IVB Colorectal Cancer AJCC v8, Stage IVC Colorectal Cancer AJCC v8
01/25
01/25
NCT05156268: A Study of Pembrolizumab and Olaparib in People With Endometrial Cancer or Endometrial Carcinosarcoma

Active, not recruiting
2
26
US
Pembrolizumab, Olaparib
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Endometrial Carcinosarcoma
01/25
01/25
NCT03746080: Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma

Active, not recruiting
2
21
US
Plerixafor, AMD 3100, JM-3100, Mozobil, SDZ SID 791, Temozolomide, CCRG-81045, Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide, 3, 4-dihydro-3-methyl-4-oxo-, M & B 39831, M and B 39831, Methazolastone, RP-46161, SCH 52365, Temcad, Temodal, Temodar, Temomedac, Whole-Brain Radiotherapy (WBRT), WBRT, whole-brain radiation therapy, whole-brain radiotherapy, Radiation Therapy, XRT, RT
Lawrence D Recht, Sanofi
Glioblastoma, Glioblastoma With Primitive Neuronal Component, Gliosarcoma, Malignant Glioma, Oligodendroglial Component Present
05/22
07/27
NCT05601232: A Phase II Study by Using CICS-1 and SPM-011 Commissioned by CICS and STELLA PHARMA

Recruiting
2
10
Japan
BNCT
Stella Pharma Corporation, Cancer Intelligence Care Systems, Inc.
Unresectable Angiosarcoma
07/24
04/25
NCT02523040: A Study of Lenalidomide for Adult Histiocyte Disorders

Active, not recruiting
2
12
US
Lenalidomide, Revlimid
Dana-Farber Cancer Institute, Celgene
Langerhans Cell Histiocytosis (LCH), Histiocytoses Erdheim-chester Disease, Histiocytic Sarcoma (HS)
02/24
08/24
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma

Recruiting
2
201
Europe, US, RoW
INBRX-109, Placebo
Inhibrx, Inc.
Conventional Chondrosarcoma
12/24
06/25
NCT05497843: Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)

Recruiting
2
40
RoW
Chiauranib, CS2164
Chipscreen Biosciences, Ltd.
Soft Tissue Sarcoma
02/24
06/24
NCT06277154: MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Not yet recruiting
2
148
RoW
MASCT-I, Doxorubicin, Doxorubicin hydrochloride for Injection, Ifosfamide, Ifosfamide for Injection
HRYZ Biotech Co.
Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Fibrosarcoma, Pleomorphic Rhabdomyosarcoma, Endometrial Stromal Sarcoma, Desmoplastic Small Round Cell Tumor
02/26
02/27
NCT01149850: Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma

Completed
2
50
US
bevacizumab, anti-VEGF humanized monoclonal antibody, anti-VEGF monoclonal antibody, anti-VEGF rhuMAb, Avastin, recombinant humanized anti-VEGF monoclonal antibody, rhuMAb VEGF, temozolomide, CCRG-81045, M & B 39831, SCH 52365, Temodal, Temodar, TMZ, laboratory biomarker analysis, immunohistochemistry staining method, immunohistochemistry, microarray analysis, gene expression profiling, DNA methylation analysis
Jonsson Comprehensive Cancer Center, Genentech, Inc.
Giant Cell Glioblastoma, Glioblastoma, Gliosarcoma
12/23
12/23
ZW25-IST-2, NCT04513665: ZW25 in Women With Endometrial Cancers

Completed
2
17
US
ZW25
Memorial Sloan Kettering Cancer Center, Zymeworks BC Inc.
Endometrial Cancer, Carcinosarcoma
03/24
03/24
NCT04551430: Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue Sarcoma

Active, not recruiting
2
105
US
Cabozantinib, Nivolumab, Opdivo, Ipilimumab, Yervoy
Washington University School of Medicine, Exelixis, Bristol-Myers Squibb
Metastatic Soft-tissue Sarcoma
06/25
06/30
NCT03069378: A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma

Active, not recruiting
2
41
US
Talimogene Laherparepvec (T-VEC), Pembrolizumab
Memorial Sloan Kettering Cancer Center, Amgen, Merck Sharp & Dohme LLC
Sarcoma, Epithelioid Sarcoma, Cutaneous Angiosarcoma
03/25
03/25
NCT04784247: Lenvatinib and Pembrolizumab in People With Advanced Soft Tissue Sarcoma

Active, not recruiting
2
52
US
Lenvatinib, Pembrolizumab
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC, Parker Institute for Cancer Immunotherapy
Advanced Sarcoma
03/25
03/25
BETA-PRIME, NCT04673942: A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors

Recruiting
2
140
US
AdAPT-001, Checkpoint Inhibitor, Immune
EpicentRx, Inc.
Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
12/25
03/27
NCT02799485: sEphB4-HSA in Treating Patients With Kaposi Sarcoma

Recruiting
2
20
US
Laboratory Biomarker Analysis, Pharmacological Study, Quality-of-Life Assessment, Quality of Life Assessment, Recombinant EphB4-HSA Fusion Protein, sEphB4-HSA
AIDS Malignancy Consortium, National Cancer Institute (NCI), Vasgene Therapeutics, Inc, The Emmes Company, LLC, University of Arkansas
Skin Kaposi Sarcoma
03/24
04/24
NCT05301283: Habitat Escalated Adaptive Therapy (HEAT), With Neoadjuvant Radiation for Soft Tissue Sarcoma

Recruiting
2
43
US
Intensity Modulated Radiation Therapy (IMRT), MRI
H. Lee Moffitt Cancer Center and Research Institute, Viewray Inc.
High Grade Sarcoma
06/24
03/25
ERASING, NCT03840772: Eribulin in Advanced Solitary Fibrous Tumor

Recruiting
2
16
Europe
Eribulin, Intervention under investigation
Italian Sarcoma Group, Eisai Inc.
Solitary Fibrous Tumor
04/24
04/24
NCT05496569: TQB3616 Capsules in the Treatment of Dedifferentiated Liposarcoma

Not yet recruiting
2
118
RoW
TQB3616 capsule, TQB3616 placebo
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Dedifferentiated Liposarcoma
04/24
12/24
PEMBROCABOSARC, NCT05182164: Combination of Pembrolizumab and Cabozantinib in Patients With Advanced Sarcomas

Recruiting
2
119
Europe
Association of pembrolizumab + cabozantinib
Institut Bergonié, Ipsen, MSD France
Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma, Ewing Sarcoma, Osteosarcoma, Undifferentiated Pleomorphic Sarcoma
04/24
10/25
ACCeSs, NCT04274023: Study on TSR-042 in Advanced Clear Cell Sarcoma

Terminated
2
3
Europe
TSR-042
Italian Sarcoma Group, GlaxoSmithKline
Sarcoma, Clear Cell
01/24
01/24
Pan-MSI-ACSE, NCT06333314: Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI

Not yet recruiting
2
120
Europe
Dostarlimab, Chemotherapy
UNICANCER, National Cancer Institute, France, GlaxoSmithKline
Pancreatic Adenocarcinoma, Ampulla of Vater Carcinoma, Adrenocortical Carcinoma, Neuroendocrine Carcinoma, Soft Tissue Sarcoma, Small Bowel Adenocarcinoma, Duodenum Adenocarcinoma, Gastric Adenocarcinoma
10/28
09/30
NCT02601950 / 2015-002469-41: A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma

Checkmark Data from a trial for epithelioid sarcoma and follicular lymphoma
Oct 2020 - Oct 2020: Data from a trial for epithelioid sarcoma and follicular lymphoma
Checkmark In adult patients with INI1-negative tumors
Oct 2018 - Oct 2018: In adult patients with INI1-negative tumors
Checkmark Epithelioid sarcoma cohort at ESMO 2018
More
Completed
2
267
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, E7438, IPN60200
Epizyme, Inc.
Malignant Rhabdoid Tumors (MRT), Rhabdoid Tumors of the Kidney (RTK), Atypical Teratoid Rhabdoid Tumors (ATRT), Selected Tumors With Rhabdoid Features, Synovial Sarcoma, INI1-negative Tumors, Malignant Rhabdoid Tumor of Ovary, Renal Medullary Carcinoma, Epithelioid Sarcoma, Poorly Differentiated Chordoma (or Other Chordoma With Sponsor Approval), Any Solid Tumor With an EZH2 GOF Mutation
02/24
02/24
CONGRATS, NCT04095208 / 2019-002332-81: Combination of Nivolumab Plus Relatlimab in Patients With Advanced or Metastatic Soft-tissue Sarcoma: a Proof-of-concept Randomized Phase II Study

Recruiting
2
67
Europe
Association of Nivolumab + Relatlimab, Nivolumab
Institut Bergonié, Bristol-Myers Squibb
Soft Tissue Sarcoma Adult, Advanced Cancer
06/24
12/25
NCT04417062: Olaparib With Ceralasertib in Recurrent Osteosarcoma

Recruiting
2
63
US
Olaparib, Lynparza, Ceralasertib, AZD6738
Dana-Farber Cancer Institute, Osteosarcoma Institute, AstraZeneca
Osteosarcoma, Osteosarcoma Recurrent
06/24
06/25
ENVASARC, NCT04480502: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma

Active, not recruiting
2
207
Europe, US
Envafolimab, KN035, Ipilimumab, Yervoy
Tracon Pharmaceuticals Inc.
Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
10/24
10/24
NCT05481645: Efficacy and Safety of TQB2450 Injection Combined With Chemotherapy ± Anlotinib Hydrochloride Capsules for Advanced Endometrial Cancer or Sarcoma of Uterus.

Recruiting
2
79
RoW
TQB2450 injection, Anlotinib Hydrochloride Capsule, Carboplatin Injection, Paclitaxel Injection, Doxorubicin Hydrochloride Injection, Gemcitabine Hydrochloride Injection, Docetaxel injection
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Endometrial Cancer, Sarcoma of Uterus
06/24
12/24
IntriNSiC, NCT05329792 / 2021-006041-36: L19IL2/L19TNF in Skin Cancer Patients

Recruiting
2
70
Europe
L19IL2/L19TNF, bifikafusp alfa/onfekafusp alfa
Philogen S.p.A., Philogen S.p.A.
BCC - Basal Cell Carcinoma, SCC - Squamous Cell Carcinoma, Merkel Cell Carcinoma, Keratoacanthoma of Skin, Malignant Adnexal Tumors of the Skin (MATS), Tumors From Cutaneous T-cell Lymphoma (CTCL), Kaposi Sarcoma
06/24
12/24
NCT06208748: SARC044: A Phase II Trial of Bezuclastinib in Combination With Sunitinib in Patients With GIST

Recruiting
2
40
US
Bezuclastinib in combination with sunitinib
Sarcoma Alliance for Research through Collaboration, Cogent Biosciences, Inc., Dana-Farber Cancer Institute, The Life Raft Group
Gastrointestinal Stromal Tumors, GIST
06/26
06/27
CabOSTar, NCT06341712: Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma

Not yet recruiting
2
90
NA
Cabozantinib, Best Supportive Care (BSC)
Ipsen
Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
10/26
06/28
NCI-2018-00918, NCT03449108: LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas

Active, not recruiting
2
30
US
Aldesleukin, 125-L-Serine-2-133-interleukin 2, Proleukin, r-serHuIL-2, Recombinant Human IL-2, Recombinant Human Interleukin-2, Autologous Tumor Infiltrating Lymphocytes LN-145, Autologous TILs LN-145, Autologous Tumor-infiltrating Lymphocytes LN-145, LN-145, LN145, Autologous Tumor Infiltrating Lymphocytes LN-145-S1, Autologous TILs LN-145-S1, Autologous Tumor-infiltrating Lymphocytes LN-145-S1, LN 145-S1, LN-145-S1, LN145-S1, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Fludarabine, Fluradosa, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
M.D. Anderson Cancer Center, Iovance Biotherapeutics, Inc., National Cancer Institute (NCI)
Bone Sarcoma, Dedifferentiated Chondrosarcoma, Giant Cell Tumor of Bone, Malignancy in Giant Cell Tumor of Bone, Malignant Solid Neoplasm, Ovarian Carcinosarcoma, Platinum-Resistant Ovarian Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Osteosarcoma, Recurrent Ovarian Carcinoma, Refractory Osteosarcoma, Soft Tissue Sarcoma, Thyroid Gland Anaplastic Carcinoma, Thyroid Gland Squamous Cell Carcinoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Triple Negative Breast Cancer
06/25
06/25
ISG-ARTICLE, NCT04383119: Trial in Patients With Metastatic or Locally Advanced Leiomyosarcoma

Recruiting
2
100
Europe
Trabectedin, Trabectedin arm, Gemcitabine, Gemcitabine arm, No Intervention: Observational Cohort
Italian Sarcoma Group, PharmaMar
Leiomyosarcoma of Ovary, Soft Tissue Sarcoma
06/24
09/24
NCT02846987: Study of Abemaciclib in Dedifferentiated Liposarcoma

Checkmark Results for dedifferentiated liposarcoma
Nov 2018 - Nov 2018: Results for dedifferentiated liposarcoma
Active, not recruiting
2
33
US
Abemaciclib, LY2835219
Memorial Sloan Kettering Cancer Center, Eli Lilly and Company
Sarcoma, Dedifferentiated Liposarcoma
07/24
07/24
DiTuSarc, NCT05080790: Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma

Recruiting
2
10
Europe
Dinutuximab Beta, Zoledronic acid, Interleukin-2
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, EUSA Pharma, Inc.
Leiomyosarcoma
07/24
07/24
NCT03241745: A Study of Nivolumab in Selected Uterine Cancer Patients

Completed
2
35
US
Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb
Uterine Cancer, Endometrial Carcinoma, Carcinosarcoma, Leiomyosarcoma, Undifferentiated Sarcoma, High Grade Endometrial Stromal Sarcoma, Clear Cell Carcinoma
04/24
04/24
NCT05854966: CPI-613 Given With Metformin in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Not yet recruiting
2
17
US
CPI 613, Devimistat, Metformin, Metformin pill, Blood draws, Bone marrow biopsy
Wake Forest University Health Sciences, National Cancer Institute (NCI), Cornerstone Pharmaceuticals
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory, Granulocytic Sarcoma
04/25
09/25
CA017-056, NCT04106414: Study of BMS-986205 and Nivolumab in Endometrial Cancer or Endometrial Carcinosarcoma That Has Not Responded to Treatment

Active, not recruiting
2
24
US
Nivolumab, BMS- 986205
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb
Endometrial Adenocarcinoma, Endometrial Carcinosarcoma
09/24
09/24
AGADIR, NCT03915678: Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors

Recruiting
2
247
Europe
Association atezolizumab + BDB001 + RT, Association atezolizumab + BDB001+ RT
Institut Bergonié, Roche Pharma AG, National Cancer Institute, France, Eikon Therapeutics
Solid Tumor, Adult, Pancreatic Cancer, Virus-associated Tumors, Non Small Cell Lung Cancer, Melanoma, Bladder Cancer, Triple Negative Breast Cancer
09/24
03/26
ISG-MCS, NCT04305548: Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma

Recruiting
2
16
Europe
Trabectedin
Italian Sarcoma Group, PharmaMar
Mesenchymal Chondrosarcoma
09/24
12/24
NCT05549921: Phase II Study of TAEST16001 in Soft Tissue Sarcoma

Recruiting
2
70
RoW
NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)
Sun Yat-sen University, Guangdong Xiangxue Precision Medical Technology Co., Ltd.
Soft Tissue Sarcoma
09/24
09/24
NCT05465954: Efineptakin Alfa and Pembrolizumab for the Treatment of Recurrent Glioblastoma

Recruiting
2
34
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Efineptakin alfa, GX-I7, Hyleukin-7 (TM), Il-7 Hybrid Fc, IL-7-hyFc, NT-I7, rhIL-7-hyFc, TJ 107, TJ-107, TJ107, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Mayo Clinic, NeoImmune Tech, Merck Sharp & Dohme LLC
High Grade Astrocytic Tumor, Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma
10/24
10/25
Actuate 1801, NCT03678883: 9-ING-41 in Patients With Advanced Cancers

Active, not recruiting
2
350
Europe, Canada, US
9-ING-41, Gemcitabine - 21 day cycle, Gemzar, Doxorubicin., Doxil, Adriamycin, Lomustine, CCNU, Gleostine, Carboplatin., Paraplatin, Nab paclitaxel., Abraxane, Protein-bound paclitaxel, Nanoparticle albumin-bound paclitaxel, Paclitaxel., Taxol, Gemcitabine - 28 day cycle, Irinotecan, Camptosar
Actuate Therapeutics Inc.
Cancer, Pancreatic Cancer, Sarcoma, Renal Cancer, Refractory Cancer, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Pancreatic Adenocarcinoma, Resistant Cancer, Neoplasm Metastasis, Neoplasm of Bone, Neoplasm, Breast, Neoplasm of Lung, Neoplasms,Colorectal, Neoplasms Pancreatic, Malignant Glioma, Malignancies, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Bone Cancer, Pancreas Cancer, Pancreatic Neoplasms, Breast Neoplasms, Acute T Cell Leukemia Lymphoma
11/24
11/25
NCT04624178: A Study of Rucaparib and Nivolumab in People With Leiomyosarcoma

Active, not recruiting
2
20
US
Rucaparib, Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb, Clovis Oncology, Inc.
Leiomyosarcoma
11/24
11/24
FIBROSARC USA, NCT03420014: Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients

Recruiting
2
114
US
Doxorubicin, L19TNF plus doxorubicin
Philogen S.p.A.
Leiomyosarcoma
12/24
12/25
NCT03993106 / 2017-001828-22: A Study of sEphB4-HSA in Kaposi Sarcoma

Recruiting
2
65
US
sEphB4-HSA
Vasgene Therapeutics, Inc
Kaposi Sarcoma
12/24
06/25
ICGTM, NCT04719156: Fluorescent Intra-operative Tumor Margin Examination

Recruiting
2
110
US
Indocyanine green solution administered at 2.0mg/kg., Indocyanine Green for Injection, Stryker SPY-PHI Imaging Device, Stryker SPY portable Imaging System
Kurt Weiss, Stryker Nordic
Sarcoma
12/24
06/25
NACHO COBI, NCT04079179: Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders

Recruiting
2
90
US
Cobimetinib, COTELLIC, RO5514041
Carl Allen, Baylor College of Medicine, North American Consortium for Histiocytosis, Genentech, Inc.
Langerhan's Cell Histiocytosis, Juvenile Xanthogranuloma, Erdheim-Chester Disease, Rosai Dorfman Disease, Neuro-Degenerative Disease, Histiocytic Sarcoma, Histiocytic Disorders, Malignant
12/24
12/29
EPOCH, NCT05619913: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma

Recruiting
2
30
Europe, Canada, RoW
Eribulin Mesylate, Halaven, Pembrolizumab, Keytruda
Australia New Zealand Gynaecological Oncology Group, Eisai Inc., Merck Sharp & Dohme LLC
Ovarian Carcinosarcoma, Uterine Carcinosarcoma
12/24
12/26
NCT05952128: Phase Ib/II Study of Fluzoparib in Combination With Dalpiciclib in Patients With Locally Advanced or Metastatic Sarcoma

Recruiting
2
50
RoW
Fluzoparib+ Dalpiciclib
Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Sarcoma
12/24
12/25
NCT06447103: An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer

Not yet recruiting
2
91
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Questionnaire Administration, Zirconium Zr 89 Girentuximab, 89Zr-DFO-TFP-girentuximab, 89Zr-girentuximab, 89Zr-TLX250, Zirconium Zr 89 cG250, Zirconium Zr 89-TLX250
Jonsson Comprehensive Cancer Center, Telix Pharmaceuticals (Innovations) Pty Limited
Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Carcinoma, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer
12/29
12/30
NCT05147558: A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine Carcinosarcoma

Recruiting
2
40
US
Pembrolizumab, Lenvatinib
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Uterine Carcinosarcoma, Advanced Uterine Carcinosarcoma
12/24
12/24
NCT02815995: Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes

Completed
2
56
US
Durvalumab, Tremelimumab
M.D. Anderson Cancer Center, MedImmune LLC
Advanced and/or Metastatic Sarcoma
06/24
06/24
STARTRK-2, NCT02568267 / 2015-003385-84: Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

Checkmark From STARTRK-2 trial in NTRK+ solid tumors
Oct 2019 - Oct 2019: From STARTRK-2 trial in NTRK+ solid tumors
Checkmark STARTRK-2 trial in NTRK+ solid tumors at ESMO 2018 [screenshot]
Oct 2018 - Oct 2018: STARTRK-2 trial in NTRK+ solid tumors at ESMO 2018 [screenshot]
Checkmark Integrated analysis of 3 trials (STARTRK-2, STARTRK-1, ALKA-372-001) in NTRK fusion-positive solid tumors
More
Active, not recruiting
2
534
Europe, Japan, US, RoW
Entrectinib, RXDX-101
Hoffmann-La Roche
Breast Cancer, Cholangiocarcinoma, Colorectal Cancer, Head and Neck Neoplasms, Lymphoma, Large-Cell, Anaplastic, Melanoma, Neuroendocrine Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Papillary Thyroid Cancer, Primary Brain Tumors, Renal Cell Carcinoma, Sarcomas, Salivary Gland Cancers, Adult Solid Tumor
12/24
04/25
NCT04195399: A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors That Cannot be Removed by Surgery

Active, not recruiting
2
35
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Echocardiography, EC, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nirogacestat, (S)-2-(((S)-6,8-Difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-N-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1H-imidazol-4-yl)pentanamide, PF-03084014, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
Children's Oncology Group, National Cancer Institute (NCI), SpringWorks Therapeutics, Inc.
Desmoid Fibromatosis, Recurrent Desmoid Fibromatosis, Unresectable Desmoid Fibromatosis
12/24
12/24
CRESTONE, NCT04383210: Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors

Active, not recruiting
2
75
Canada, US, RoW
Seribantumab
Elevation Oncology
Locally Advanced Solid Tumor, Metastatic Solid Tumor, Pancreatic Cancer, Lung Cancer, Head and Neck Cancer, Breast Cancer, Kidney Cancer, Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Sarcoma, Gallbladder Cancer, Bile Duct Cancer, Esophageal Cancer, Uterine Cancer, Cholangiocarcinoma, Prostate Cancer
01/25
03/25
NCT03601806: Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection

Active, not recruiting
2
26
RoW
Laboratory Biomarker Analysis, Pomalidomide, 4-Amino thalidomide, Actimid, CC-4047, Imnovid, Pomalyst
AIDS Malignancy Consortium, National Cancer Institute (NCI), The Emmes Company, LLC, University of Arkansas, Montefiore Medical Center, University of Stellenbosch, Weill Medical College of Cornell University, University of California, Los Angeles
Human Immunodeficiency Virus 1 Positive, Skin Kaposi Sarcoma
11/24
01/26
TOMAS2, NCT03838744 / 2018-004497-10: Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.

Active, not recruiting
2
126
Europe
Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm
Italian Sarcoma Group, PharmaMar, AstraZeneca
Advanced Soft Tissue Sarcoma
02/25
02/25
TORNADO, NCT04968106: Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas

Recruiting
2
66
Europe
Doxorubicin, Ifosfamide, INCMGA00012, Retifanlimab
Institut Bergonié, Incyte Biosciences International Sàrl
Resectable Sarcoma
03/25
10/27
NCT05580588: Open-Label Study of the CDK4/6 Inhibitor SPH4336 in Subjects With Locally Advanced or Metastatic Liposarcomas

Recruiting
2
33
US
SPH4336
Shanghai Pharma Biotherapeutics USA Inc.
Liposarcoma, Dedifferentiated
03/25
03/25
TORAN, ChiCTR2100054901: A phase II trial of anlotinib and toripalimab as maintenance therapy in patients with advanced soft tissue sarcoma after anthracycline-based chemotherapy

Recruiting
2
50
China
Anlotinib + Toripalimab
West China Hospital, Sichuan University ; West China Hospital, Sichuan University, West China Hospital, Sichuan University; Shanghai Junshi Biosciences Co., Ltd.; Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Soft tissue sarcoma
 
 
REFIT-MSS, NCT05582031: Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers

Withdrawn
2
322
NA
Regorafenib in combination with Tislelizumab
Translational Research in Oncology, Bayer, Novartis
Anal Squamous Cell Carcinoma, Colorectal Neoplasms, Soft Tissue Sarcoma, Malignant Pleural Mesothelioma, Small Cell Lung Carcinoma, Castrate Resistant Prostate Cancer, Neuroendocrine Carcinoma of Prostate, Gastroenteropancreatic Neuroendocrine Neoplasm
04/25
04/25
 

Download Options